IL-12 protects from psoriasiform skin inflammation

Nature Communications

Volumn 7, Issue , 2016, Pages

  Kulig, Paulina ^a   Musiol, Stephanie ^b   Freiberger, Sandra Nicole ^c   Schreiner, Bettina ^a   Gyu'lveszi, Gabor ^d   Russo, Giancarlo ^a   Pantelyushin, Stanislav ^a   Kishihara, Kenji ^e   Alessandrini, Francesca ^b   Ku'ndig, Thomas ^c   Sallusto, Federica ^d   Hofbauer, Gunther F L ^c   Haak, Stefan ^b   Becher, Burkhard ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d INSTITUTE FOR RESEARCH IN BIOMEDICINE   (Switzerland)

^e NAGASAKI INTERNATIONAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 17 RECEPTOR; INTERLEUKIN 23; AMINOQUINOLINE DERIVATIVE; IMIQUIMOD; LYMPHOCYTE ANTIGEN RECEPTOR;

ANTIBODY; DISEASE SEVERITY; IMMUNITY; NUMERICAL MODEL; PROTEIN; SKIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DERMATITIS; GAMMA DELTA T LYMPHOCYTE; KERATINOCYTE; MOUSE; NONHUMAN; PSORIASIS; SIGNAL TRANSDUCTION; T LYMPHOCYTE SUBPOPULATION; ANIMAL; C57BL MOUSE; COMPLICATION; DRUG EFFECT; FEMALE; HUMAN; INFLAMMATION; METABOLISM; PATHOLOGY; SKIN;

AMINOQUINOLINES; ANIMALS; FEMALE; HUMANS; INFLAMMATION; INTERLEUKIN-12; INTERLEUKIN-23; KERATINOCYTES; MICE, INBRED C57BL; PSORIASIS; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; SKIN;

EID: 85000399156     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms13466     Document Type: Article

References (70)

1. Lowes, M. A., Suarez-Farinas, M., & Krueger, J. G. Immunology of psoriasis. Annu. Rev. Immunol. 32, 227-255 (2014).
2. Kagami, S., Rizzo, H. L., Lee, J. J., Koguchi, Y., & Blauvelt, A. Circulating Th17, Th22, and Th1 cells are increased in psoriasis. J. Invest. Dermatol. 130, 1373-1383 (2010).
3. Zaba, L. C., et al. Psoriasis is characterized by accumulation of immunostimulatory and Th1/Th17 cell-polarizing myeloid dendritic cells. J. Invest. Dermatol. 129, 79-88 (2009).
4. Yawalkar, N., Tscharner, G. G., Hunger, R. E., & Hassan, A. S. Increased expression of IL-12p70 and IL-23 by multiple dendritic cell and macrophage subsets in plaque psoriasis. J. Dermatol. Sci. 54, 99-105 (2009).
5. Piskin, G., Sylva-Steenland, R. M., Bos, J. D., & Teunissen, M. B. In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin. J. Immunol. 176, 1908-1915 (2006).
6. Langley, R. G., et al. Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis. J. Eur. Acad. Dermatol. Venereol. 27, 1252-1261 (2013).
7. Papp, K. A., et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 371, 1675-1684 (2008).
8. Papp, K. A., et al. Long-Term safety of ustekinumab in patients with moderateto-severe psoriasis: final results from 5 years of follow-up. Br. J. Dermatol. 168, 844-854 (2013).
9. Kimball, A. B., et al. Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial. Arch. Dermatol. 144, 200-207 (2008).
10. Di Cesare, A., Di Meglio, P., & Nestle, F. O. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J. Invest. Dermatol. 129, 1339-1350 (2009).
11. Chan, J. R., et al. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J. Exp. Med. 203, 2577-2587 (2006).
12. Cai, Y., et al. Pivotal role of dermal IL-17-producing gammadelta T cells in skin inflammation. Immunity 35, 596-610 (2011).
13. van der Fits, L., et al. Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J. Immunol. 182, 5836-5845 (2009).
14. Nair, R. P., et al. Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat. Genet. 41, 199-204 (2009).
15. Heilig, J. S., & Tonegawa, S. Diversity of murine gamma genes and expression in fetal and adult T lymphocytes. Nature 322, 836-840 (1986).
16. Pantelyushin, S., et al. Rorgammat+ innate lymphocytes and gammadelta T cells initiate psoriasiform plaque formation in mice. J. Clin. Invest. 122, 2252-2256 (2012).
17. Gray, E. E., Suzuki, K., & Cyster, J. G. Cutting edge: Identification of a motile IL-17-producing gammadelta T cell population in the dermis. J. Immunol. 186, 6091-6095 (2011).
18. Papp, K. A., et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N. Engl. J. Med. 366, 1181-1189 (2012).
19. Leonardi, C., et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N. Engl. J. Med. 366, 1190-1199 (2012).
20. Hueber, W., et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci. Transl. Med. 2, 52ra72 (2010).
21. Sofen, H., et al. Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-To-severe psoriasis. J. Allergy Clin. Immunol. 133, 1032-1040 (2014).
22. Lee, E., et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J. Exp. Med. 199, 125-130 (2004).
23. Croxford, A. L., Mair, F., & Becher, B. IL-23: one cytokine in control of autoimmunity. Eur. J. Immunol. 42, 2263-2273 (2012).
24. Vignali, D. A., & Kuchroo, V. K. IL-12 family cytokines: immunological playmakers. Nat. Immunol. 13, 722-728 (2012).
25. Hong, K., Chu, A., Ludviksson, B. R., Berg, E. L., & Ehrhardt, R. O. IL-12, independently of IFN-gamma, plays a crucial role in the pathogenesis of a murine psoriasis-like skin disorder. J. Immunol. 162, 7480-7491 (1999).
26. Tonel, G., et al. Cutting edge: a critical functional role for IL-23 in psoriasis. J. Immunol. 185, 5688-5691 (2010).
27. Austin, L. M., Ozawa, M., Kikuchi, T., Walters, I. B., & Krueger, J. G. The majority of epidermal T cells in Psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-Alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J. Invest. Dermatol. 113, 752-759 (1999).
28. Yawalkar, N., Karlen, S., Hunger, R., Brand, C. U., & Braathen, L. R. Expression of interleukin-12 is increased in psoriatic skin. J. Invest. Dermatol. 111, 1053-1057 (1998).
29. Lebwohl, M., et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N. Engl. J. Med. 373, 1318-1328 (2015).
30. Thaci, D., et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J. Am. Acad. Dermatol. 73, 400-409 (2015).
31. Papp, K., et al. in Arthritis & Rheumatology Vol. 67 (Wiley-Blackwell, 2015).
32. Berardesca, E., & Maibach, H. I. Noninvasive bioengineering assessment of psoriasis. Int. J. Dermatol. 28, 157-160 (1989).
33. Cai, Y., et al. Differential developmental requirement and peripheral regulation for dermal Vgamma4 and Vgamma6T17 cells in health and inflammation Nat. Commun. 5, 3986 (2014).
34. Hara, H., et al. Development of dendritic epidermal T cells with a skewed diversity of gamma delta TCRs in V delta 1-deficient mice. J. Immunol. 165, 3695-3705 (2000).
35. Hamada, S., et al. Importance of murine Vdelta1gammadelta T cells expressing interferon-gamma and interleukin-17A in innate protection against Listeria monocytogenes infection. Immunology 125, 170-177 (2008).
36. Sawant, D. V., Hamilton, K., & Vignali, D. A. Interleukin-35: expanding its job profile. J. Interferon Cytokine Res. 35, 499-512 (2015).
37. Trinchieri, G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol. 3, 133-146 (2003).
38. Sugaya, M., Nakamura, K., & Tamaki, K. Interleukins 18 and 12 synergistically upregulate interferon-gamma production by murine dendritic epidermal T cells. J. Invest. Dermatol. 113, 350-354 (1999).
39. Di Meglio, P., et al. Activation of the aryl hydrocarbon receptor dampens the severity of inflammatory skin conditions. Immunity 40, 989-1001 (2014).
40. Witherden, D. A., & Havran, W. L. Cross-Talk between intraepithelial gammadelta T cells and epithelial cells. J. Leukoc. Biol. 94, 69-76 (2013).
41. Li, Y., et al. Exogenous stimuli maintain intraepithelial lymphocytes via aryl hydrocarbon receptor activation. Cell 147, 629-640 (2011).
42. Lowes, M. A., Russell, C. B., Martin, D. A., Towne, J. E., & Krueger, J. G. The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses. Trends Immunol. 34, 174-181 (2013).
43. Bouchaud, G., et al. Epidermal IL-15Ralpha acts as an endogenous antagonist of psoriasiform inflammation in mouse and man. J. Exp. Med. 210, 2105-2117 (2013).
44. Schwarz, A., et al. Interleukin-12 suppresses ultraviolet radiation-induced apoptosis by inducing DNA repair. Nat. Cell Biol. 4, 26-31 (2002).
45. Schwarz, A., et al. Prevention of UV radiation-induced immunosuppression by IL-12 is dependent on DNA repair. J. Exp. Med. 201, 173-179 (2005).
46. Schmitt, D. A., Walterscheid, J. P., & Ullrich, S. E. Reversal of ultraviolet radiation-induced immune suppression by recombinant interleukin-12: suppression of cytokine production. Immunology 101, 90-96 (2000).
47. Molenda, M., Mukkamala, L., & Blumenberg, M. Interleukin IL-12 blocks a specific subset of the transcriptional profile responsive to UVB in epidermal keratinocytes. Mol. Immunol. 43, 1933-1940 (2006).
48. Perera, G. K., Di Meglio, P., & Nestle, F. O. Psoriasis. Annu. Rev. Pathol. 7, 385-422 (2012).
49. Gudjonsson, J. E., et al. Assessment of the psoriatic transcriptome in a large sample: additional regulated genes and comparisons with in vitro models. J. Invest. Dermatol. 130, 1829-1840 (2010).
50. Chiricozzi, A., et al. Integrative responses to IL-17 and TNF-Alpha in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. J. Invest. Dermatol. 131, 677-687 (2011).
51. Leonardi, C. L., et al. Etanercept as monotherapy in patients with psoriasis. N. Engl. J. Med. 349, 2014-2022 (2003).
52. Croxford, A. L., Kulig, P., & Becher, B. IL-12-And IL-23 in health and disease. Cytokine Growth Factor Rev. 25, 415-421 (2014).
53. Cua, D. J., et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 421, 744-748 (2003).
54. Becher, B., Durell, B. G., & Noelle, R. J. Experimental autoimmune encephalitis and inflammation in the absence of interleukin-12. J. Clin. Invest. 110, 493-497 (2002).
55. Gran, B., et al. IL-12p35-deficient mice are susceptible to experimental autoimmune encephalomyelitis: evidence for redundancy in the IL-12 system in the induction of central nervous system autoimmune demyelination. J. Immunol. 169, 7104-7110 (2002).
56. Kopp, T., et al. Clinical improvement in psoriasis with specific targeting of interleukin-23. Nature 521, 222-226 (2015).
57. Reich, K., et al. A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis. N. Engl. J. Med. 365, 1586-1596 (2011).
58. Gordon, K. B., et al. Long-Term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials. J. Am. Acad. Dermatol. 66, 742-751 (2012).
59. Young, L., & Czarnecki, D. The rapid onset of multiple squamous cell carcinomas in two patients commenced on ustekinumab as treatment of psoriasis. Australas. J. Dermatol. 53, 57-60 (2012).
60. Ngiow, S. F., Teng, M. W., & Smyth, M. J. A balance of interleukin-12 and-23 in cancer. Trends Immunol. 34, 548-555 (2013).
61. Tugues, S., et al. New insights into IL-12-mediated tumor suppression. Cell Death Differ. 22, 237-246 (2015).
62. Gordon, K. B., et al. A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-To-severe psoriasis. J. Invest. Dermatol. 132, 304-314 (2012).
63. Laggner, U., et al. Identification of a novel proinflammatory human skinhoming Vgamma9Vdelta2 T cell subset with a potential role in psoriasis. J. Immunol. 187, 2783-2793 (2011).
64. Seung, N. R., et al. Comparison of expression of heat-shock protein 60, Toll-like receptors 2 and 4, and T-cell receptor gammadelta in plaque and guttate psoriasis. J. Cutan. Pathol. 34, 903-911 (2007).
65. Swindell, W. R., Johnston, A., Voorhees, J. J., Elder, J. T., & Gudjonsson, J. E. Dissecting the psoriasis transcriptome: inflammatory-and cytokine-driven gene expression in lesions from 163 patients. BMC Genomics 14, 527 (2013).
66. Banno, T., Gazel, A., & Blumenberg, M. Effects of tumor necrosis factor-Alpha (TNF alpha) in epidermal keratinocytes revealed using global transcriptional profiling. J. Biol. Chem. 279, 32633-32642 (2004).
67. Vom Berg, J., et al. Intratumoral IL-12 combined with CTLA-4 blockade elicits T cell-mediated glioma rejection. J. Exp. Med. 210, 2803-2811 (2013).
68. Dobin, A., et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15-21 (2013).
69. Lawrence, M., et al. Software for computing and annotating genomic ranges. PLoS Comput. Biol. 9, e1003118 (2013).
70. Robinson, M. D., McCarthy, D. J., & Smyth, G. K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139-140 (2010).